Ask AI
ProCE Banner Activity

FLAURA2: OS Outcomes by Baseline Prognostic Factors in EGFR-Mutated NSCLC Receiving 1L Osimertinib ± Platinum-Based CT

Conference Coverage
Slideset

In this exploratory analysis of the phase III FLAURA2 trial, treatment of EGFR-mutant advanced NSCLC with first-line osimertinib with platinum-based chemotherapy yielded statistically significant and clinically meaningful improvement in OS across molecular and clinical prognostic subgroups compared with osimertinib alone. 

Released: October 23, 2025

Share

Provided by

Provided by Clinical Care Options, LLC

ProCE Banner

Supporters

Supported by educational grants from AstraZeneca, Daiichi Sankyo, Inc., Gilead Sciences, Inc., Incyte, and Lilly.

AstraZeneca

Daiichi Sankyo, Inc.

Gilead Sciences, Inc.

Incyte

Lilly